INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

For the key trials, our articles and recipes, read the Atherosclerosis & Heart Disease desk →

1,829 studies · page 33 of 77

2020 / Narrative review

A review indicates high sodium intake is directly related to increased blood pressure, target organ damage, and elevated cardiovascular risk.

This review examines evidence on sodium intake and target organ damage in hypertension. The authors report that current global sodium consumption exceeds safe levels and that sodium intake is directly related to increased blood pressure and independently to cardiac mass enlargement. High sodium intake may also induce renal damage progression in both hypertensive and normotensive individuals and play an adverse role in cerebrovascular disease.

Nista F, Gatto F, Albertelli M, et al. Int J Environ Res Public Health, 2020. PMID 32325839

2020 / Narrative review

Elevated serum erythritol predicts future central adiposity gain and type 2 diabetes mellitus in healthy adults.

This review summarizes recent findings on mammalian erythritol metabolism and its role as a predictive biomarker for cardiometabolic disease risk. Elevated serum erythritol predicts future central adiposity gain and type 2 diabetes mellitus in healthy adults. Erythritol is an endogenously synthesized product of glucose via the pentose phosphate pathway, with the final conversion catalyzed by sorbitol dehydrogenase and alcohol dehydrogenase 1. Additionally, dietary erythritol can be metabolized to erythrose or erythronate in humans before excretion, highlighting the need to evaluate the effects of long-term consumption.

Shows an association, not proof of cause and effect.

Ortiz SR, Field MS Curr Opin Clin Nutr Metab Care, 2020. PMID 32412980

2020 / Narrative review

Nicotinamide riboside elevates NAD+ and shows therapeutic potential for metabolic, cardiovascular, neurodegenerative, and infectious disorders.

This review summarizes data on nicotinamide riboside (NR), an NAD+ precursor studied for its health benefits mediated through elevated NAD+ content. Evidence from animal and human studies indicates effectiveness in treating cardiovascular, neurodegenerative, and metabolic disorders, as well as emerging potential against pathogens such as SARS-CoV-2. The review also discusses challenges related to NR's bioavailability and safety, and compares it to other NAD+ precursors.

Mehmel M, Jovanović N, Spitz U Nutrients, 2020. PMID 32486488

2020 / Guideline

The American Cancer Society updated its diet and physical activity guidelines for cancer prevention, adding community action recommendations.

The American Cancer Society updated its Diet and Physical Activity Guideline based on current scientific evidence regarding dietary and physical activity patterns and cancer risk. The guideline presents 4 recommendations for individual choices alongside recommendations for community action to create supportive environments. These recommendations align with prevention guidelines for coronary heart disease and diabetes from the American Heart Association and the American Diabetes Association.

Rock CL, Thomson C, Gansler T, et al. CA Cancer J Clin, 2020. PMID 32515498

2020 / Narrative review

A review notes lifestyle modifications like low sodium diet and weight loss can help control hypertension in African Americans.

This review examined literature from PubMed, guideline reports, and newer publications regarding hypertension and COVID-19 in African Americans. It highlights that the increased prevalence and risks of hypertension are primarily due to environmental and lifestyle factors, such as poor diet and adverse social determinants. Blood pressure control can be supported through lifestyle changes, including a low-sodium diet, weight loss, and physical activity, alongside pharmacological or novel treatments when needed. Additionally, existing comorbidities like hypertension and obesity contribute to worse COVID-19 outcomes in this population.

Ferdinand K, Batieste T, Fleurestil M J Natl Med Assoc, 2020. PMID 32563685

2020 / Narrative review

A plant-dominant low-protein diet may help slow CKD progression and control uremia to delay dialysis initiation.

Chronic kidney disease affects more than 10% of the adult population, with many transitioning annually to dialysis. This review examines a plant-dominant low-protein diet (PLADO) providing 0.6–0.8 g/kg/day with >50% plant-based protein. The authors discuss that high meat intake increases intraglomerular pressure, hyperfiltration, nitrogenous waste, and cardiovascular risk. Conversely, a fiber-rich plant-dominant diet may favorably alter the gut microbiome, decrease uremic toxin production, and slow CKD progression.

Kalantar-Zadeh K, Joshi S, Schlueter R, et al. Nutrients, 2020. PMID 32610641

2020 / Narrative review with systematic search

A review of 43 studies found ultra-processed food consumption was linked to at least one adverse health outcome in 37 studies, with no beneficial outcomes found.

This narrative review systematically searched and appraised studies examining associations between ultra-processed food (UPF) intake and health outcomes in healthy participants. Out of 43 reviewed studies, 37 found UPF exposure was associated with at least one adverse health outcome. In adults, reported associations included overweight, obesity, cardio-metabolic risks, cancer, type-2 diabetes, cardiovascular diseases, irritable bowel syndrome, depression, frailty conditions, and all-cause mortality; in children and adolescents, outcomes included cardio-metabolic risks and asthma. No study reported an association between UPF and beneficial health outcomes, and the authors note that most findings were derived from observational studies.

Shows an association, not proof of cause and effect.

Elizabeth L, Machado P, Zinöcker M, et al. Nutrients, 2020. PMID 32630022

2020 / Narrative review

Current evidence on the safety and efficacy of low-calorie and non-calorie sweeteners remains scarce and controversial.

This narrative review summarizes current evidence regarding the neuroendocrine and metabolic effects of low- and non-calorie sweeteners, including their impact on the central nervous system, gut hormones, and gut microbiota. While sweeteners may help reduce calorie intake and prevent weight gain, studies examining their short- and long-term safety and efficacy are scarce and controversial. The authors note the need for future studies to elucidate beneficial and detrimental effects across healthy populations and those with metabolic disorders, and discuss sweetener use in very-low calorie ketogenic diets.

Moriconi E, Feraco A, Marzolla V, et al. Front Endocrinol (Lausanne), 2020. PMID 32765425

2020 / Narrative review

Consuming 2-3 g of plant stanol esters per day reduces LDL-C concentrations by an average of 9-12%.

This review discusses dietary strategies for the prevention of atherosclerotic cardiovascular diseases (ASCVDs), focusing on plant stanol esters. Plant stanols, as fatty-acid esters, lower cholesterol absorption, transport less cholesterol to the liver, and upregulate LDL receptor expression. Consuming 2-3 g of plant stanol esters daily reduces LDL-C concentrations on average by 9-12%. The authors propose that plant stanol esters as part of a heart-healthy diet offer a plausible means to reduce ASCVD event risk at a population level.

Gylling H, Strandberg TE, Kovanen PT, et al. Nutrients, 2020. PMID 32781511

2020 / Narrative review

Functional foods and supplements that lower LDL-C can help reduce CVD risk in both general prevention and care-related management.

This review evaluates functional foods and supplements that lower serum LDL-C across the spectrum of CVD prevention. It reports that any decrease in serum LDL-C is associated with reduced CVD risk, with benefits from dietary interventions comparable to drug treatments. The authors highlight evidence for functional ingredients in universal prevention as well as care-related management, such as in statin-intolerant patients or those failing to reach target levels. Practical aspects, including shared decision-making and cost barriers, are also discussed.

Baumgartner S, Bruckert E, Gallo A, et al. Atherosclerosis, 2020. PMID 32861515

2020 / Narrative review

A review discusses NAD+ metabolism and the progress of NAD+-boosting therapies in cardiovascular diseases linked to sudden cardiac death.

This review examines the fundamentals of NAD+ homeostasis and its role as a co-substrate for proteins such as sirtuins, poly(ADP-ribose) polymerases, and cyclic ADP-ribose synthetases. It covers molecular physiology and recent advances in ischemic-reperfusion injury, heart failure, and arrhythmias associated with sudden cardiac death risk. Additionally, the authors summarize the progress of NAD+-boosting therapy in human cardiovascular diseases and discuss challenges for future studies.

Xu W, Li L, Zhang L Front Physiol, 2020. PMID 32903597

2020 / Review of a population-based lifestyle intervention project

The North Karelia Project's community lifestyle interventions were followed by major reductions in CVD risk factors and mortality in Finland.

Initiated in 1972 in response to high cardiovascular mortality among men in North Karelia, the project targeted lifestyle changes through community-based interventions and national policy changes. Dietary recommendations emphasized reducing saturated fat and decreasing salt intake, alongside smoking reduction targets. Following the interventions, which expanded across Finland, significant reductions were observed in serum cholesterol levels, hypertension, smoking prevalence, and cardiovascular disease mortality.

Puska P, Jaini P Am J Lifestyle Med, 2020. PMID 32922234

2020 / Narrative review of clinical trials

Omega-3 fatty acids produce variable cardiovascular effects depending on their specific formulation and dosage.

This review summarizes findings from contemporary clinical trials investigating the cardioprotective effects of omega-3 fatty acids, specifically EPA and DHA. While early trials showed cardiovascular benefits with fish oils, subsequent studies largely failed to replicate these results. Recent trials have shown cardiovascular risk reduction with high-dose EPA, but not with lower doses or a carboxylic acid formulation combining EPA and DHA.

NANO counterpoint →

Nicholls SJ, Nelson AJ Curr Opin Lipidol, 2020. PMID 33027227

2020 / Narrative review and proposal

A stepwise management approach based on lifestyle interventions and lipid-lowering therapy is proposed for low-CVD-risk individuals with elevated LDL-C.

Existing guidelines show considerable inconsistency regarding the management of patients at low overall cardiovascular disease (CVD) risk who have persistently elevated LDL-C. Authors propose a step-by-step practical approach for individuals with low (< 1%) 10-year CVD risk and elevated LDL-C (> 140 mg/dL, 3.6 mmol/L). The strategy is based on adherence to lifestyle interventions, with stepwise management including lipid-lowering therapy if non-adherent, targeting LDL-C levels < 115 mg/dL (3.0 mmol/L). The authors note further studies are needed to determine the long-term efficacy, safety, and cost-effectiveness of this approach.

Penson PE, Pirro M, Banach M BMC Med, 2020. PMID 33032586

2020 / State-of-the-art review

Adverse coronary heart disease events can be mitigated or avoided with lifestyle and risk factor modifications and medical therapy.

This review evaluates scientific evidence for medical therapy and revascularization in patients with stable coronary heart disease. It notes that adverse events can be mitigated or avoided through lifestyle and risk factor modifications alongside medical therapy. The authors discuss implications for patient evaluation and public policy, highlighting that revascularization is largely confined to specific high-risk subgroups.

Ferraro R, Latina JM, Alfaddagh A, et al. J Am Coll Cardiol, 2020. PMID 33153586

2019 / Narrative review

Increasing potassium intake lowers blood pressure, especially in hypertensive individuals, and reduces stroke risk by about 25%.

This review evaluates evidence on potassium intake for blood pressure control in essential hypertension and its safety in chronic kidney disease. Over 40 years of evidence demonstrates that increasing potassium intake through foods or supplements is associated with significant reductions in systolic and diastolic blood pressure, particularly in hypertensive patients and those with high sodium intake. Meta-analyses confirm high potassium intake reduces stroke risk by ~25%, and post hoc analyses suggest it may slow renal decline in early CKD. However, high potassium intake may be risky in hypertensive patients with CKD stages 3-5, specifically diabetics, though more prospective studies are needed.

Burnier M Nephrol Dial Transplant, 2019. PMID 29301002

2019 / Literature review of experimental trials

In healthy adults, probiotics may improve immune, GI, and female reproductive health, but do not persistently alter microbiota or improve lipid profiles.

A review of literature from 1990 to August 2017 analyzed 45 experimental trials testing live probiotic bacteria in healthy adults. Probiotic supplementation led to transient increases in supplement-specific gut bacteria, but failed to show persistent microbiota changes. Evidence supported improvements in immune system responses, stool consistency, bowel movements, and vaginal lactobacilli concentration, but found insufficient evidence to support improvements in blood lipid profiles.

Khalesi S, Bellissimo N, Vandelanotte C, et al. Eur J Clin Nutr, 2019. PMID 29581563

2019 / Narrative review

Foods fortified with 2-3 g/day of plant sterols or stanols lower LDL-cholesterol by 9-12% across various clinical settings.

This review summarizes evidence on plant sterol and stanol (PS) fortified foods for managing hypercholesterolemia. Meta-analyses of over 100 controlled clinical trials demonstrate that 2-3 g per day of PS yields a 9-12% reduction in LDL-cholesterol. In patients taking statins, the average LDL reduction with PS equals up-titrating the statin dose twice. A key limitation noted is the current lack of clinical trials evaluating the effects of PS on cardiovascular events.

Cofán M, Ros E Curr Med Chem, 2019. PMID 29984649

2019 / Narrative review

A review reports that about 130 human clinical trials of resveratrol have yielded varying results, alongside a pristine safety profile.

This narrative review discusses the history and development of resveratrol research. Around 130 human clinical trials have been conducted or are underway with varying results, potentially due to disparate doses ranging from approximately 5 to 5,000 mg/day and variable experimental settings. Molecular targets are numerous without a dominant mechanism, but resveratrol maintains a pristine safety profile and widespread use as a dietary supplement. The author suggests future investigation is warranted, noting potential promise for topical preparations and conditions responsive to anti-inflammatory action or direct exposure, such as colon cancer prevention.

Pezzuto JM Biomol Ther (Seoul), 2019. PMID 30332889

2019 / Narrative review of two prospective cohort studies

In AHS-2 and EPIC-Oxford cohorts, vegetarian diets were linked to lower cancer and mortality risks and substantially reduced greenhouse gas emissions.

Researchers reviewed publications from the AHS-2 and EPIC-Oxford cohorts to describe the dietary intakes, health effects, and environmental outcomes of vegetarian patterns. In AHS-2, vegans had a 16% reduced risk of all cancers, while vegans, vegetarians, and fish-eaters in EPIC-Oxford showed an 11-19% lower risk compared to non-vegetarians. Pesco-vegetarians in AHS-2 had significantly lower all-cause and ischemic heart disease mortality, and EPIC-Oxford fish-eaters had significantly lower all-cancer mortality versus non-vegetarians. Greenhouse gas emissions of equicaloric diets were 29% lower for vegetarian diets in AHS-2 and 47-60% lower for vegetarian/vegan diets in EPIC-Oxford compared to non-vegetarian/meat-eating diets.

Shows an association, not proof of cause and effect.

Segovia-Siapco G, Sabaté J Eur J Clin Nutr, 2019. PMID 30487555

2019 / Narrative review

A review suggests plant-based diets may offer cardiovascular safety and performance advantages for endurance athletes.

This review examined the role of plant-based diets in addressing cardiovascular risks and performance in endurance athletes, who studies suggest face higher-than-average risk for atherosclerosis and myocardial damage. The effect of plant-based diets on risk factors such as plasma lipids, body weight, blood pressure, and reversing existing atherosclerotic lesions may provide substantial cardiovascular protection. Furthermore, plant-based diets have consistently been shown to reduce body fat and indicators of inflammation, foster glycogen storage, and help reduce oxidative stress. By reducing blood viscosity and improving arterial flexibility and endothelial function, they may be expected to improve vascular flow and tissue oxygenation.

Barnard ND, Goldman DM, Loomis JF, et al. Nutrients, 2019. PMID 30634559

2019 / Clinical review of clinical trials

A review of 77 clinical studies highlights the lipid-lowering and insulin-resistance improving effects of berberine with low toxicity.

This review examined clinical trials on Berberis vulgaris and its alkaloid constituent berberine across electronic databases. Across 77 human clinical studies, lipid-lowering and insulin-resistance improving actions were the most frequently studied properties, alongside cardiovascular, anticancer, gastrointestinal, CNS, and endocrine applications. Berberine demonstrated very low toxicity at usual doses with no major side effects, though mild gastrointestinal reactions occurred in some patients.

Imenshahidi M, Hosseinzadeh H Phytother Res, 2019. PMID 30637820

2019 / Narrative review

Meeting or exceeding recommended physical activity levels supports longevity, with maximal benefits seen at three to five times the minimum recommendations.

This review examined recent evidence regarding the dose and type of physical activity that promotes longevity and disease-free aging. Meeting at least 150 minutes per week of moderate-intensity leisure time aerobic activity provides most longevity benefits, while higher duration and intensity augment cardiovascular and metabolic effects. Performing three to five times the minimum recommended physical activity achieves maximal longevity benefit, though benefit may decrease with even higher amounts. High maximal oxygen uptake in mid-life serves as a strong marker of longevity, and muscle mass is a critical prognostic factor in aging and cancer.

Pedersen BK Curr Opin Clin Nutr Metab Care, 2019. PMID 30640736

2019 / Narrative review of clinical trials

Resveratrol shows therapeutic potential across various diseases in over 244 clinical trials and is reported safe at doses up to 5 g/day.

This review evaluates clinical evidence on the polyphenolic nutraceutical resveratrol, whose efficacy, safety, and pharmacokinetics have been documented in over 244 clinical trials with 27 ongoing. Resveratrol is reported to potentially improve therapeutic outcomes in conditions such as diabetes mellitus, obesity, cancers, metabolic syndrome, hypertension, Alzheimer's disease, cardiovascular diseases, and kidney diseases. It is reported to be safe at doses up to 5 g/day alone or in combination therapy. However, its therapeutic use is limited by rapid metabolism and poor bioavailability, though a micronized formulation (SRT501) shows promise.

Singh AP, Singh R, Verma SS, et al. Med Res Rev, 2019. PMID 30741437